<div id="readability-page-1" class="page"><div> Here are some of the main factors that may affect Swiss stocks on Wednesday:ALCON AG Alcon completed its $750 Million share repurchase program. UBS The Swiss lender is also considering external CEO candidates, CEO Ermotti saysROCHE Genentech said on Tuesday it will more than double its initial investment in a biomanufacturing facility in North Carolina to about $2 billion, as the companies look to further boost their $50 billion investment in the U.S.BARRY CALLEBAUT AG The Swiss chocolate maker said it appointed Hein Schumacher as the new CEO of the company, effective January 26.COMPANY STATEMENTSBARRY CALLEBAUT Q1 results due at 0700 GMTANALYSTS' VIEWSPARTNERS GROUP HOLDING AG : Jefferies cuts target price to CHF 1,130 from CHF 1,150ECONOMYSwiss December money supply M3 due at 0900 GMTSNB US Dollar auction due at 1000 GMT</div></div>

Swiss stocks may be influenced by several factors on January 21. ALCON AG has completed a $750 million share repurchase program. UBS is considering external CEO candidates, according to CEO Ermotti. ROCHE's Genentech plans to increase its investment in a North Carolina biomanufacturing facility to $2 billion. BARRY CALLEBAUT AG appointed Hein Schumacher as its new CEO, effective January 26, with Q1 results expected at 0700 GMT. Jefferies has cut the target price for PARTNERS GROUP HOLDING AG to CHF 1,130. Swiss December money supply M3 and SNB US Dollar auction are also due.

Reuters

ALPS Medical Breakthrough

VG Health

SPDR S&P Biotech

Ark Genomic Revolution ETF

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

Molecular Partners

Invesco Nasdaq Biotechnology ETF

Roche

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

iShares US Medical Devices

Alcon

VanEck Biotech ETF

ROCHE HOLDINGS AG

iShares Biotechnology ETF

Direxion S&P Biotech Bear 3X

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Swiss stocks - Factors to watch on January 21